Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia
John F. Seymour(The Royal Melbourne Hospital), Stephan Stilgenbauer(Universität Ulm), Andrew W. Roberts(The Royal Melbourne Hospital), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Andrea Best(AbbVie (United States)), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Michael Hallek(Integrated Oncology (United States)), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Su Young Kim(Yonsei University), Todd Busman(Abbott Fund), Elisa Cerri(AbbVie (United States)), Maria Verdugo(AbbVie (United States)), Monali Desai(AbbVie (United States))
Cited by 10
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k